Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021
March 10, 2021 17:00 ET
|
Achilles Therapeutics
Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021 London, UK 10 March 2021 – Achilles Therapeutics plc (“Achilles” or the “Company”), a...
Achilles Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering in the United States
March 01, 2021 18:26 ET
|
Achilles Therapeutics
Achilles Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering in the United States London, UK 1 March 2021 – Achilles Therapeutics plc (“Achilles” or the...
Achilles Therapeutics Announces Independent Data and Safety Monitoring Committee Review with a Positive Recommendation to Continue with Current Study Design of the Phase I/IIa CHIRON and THETIS Trials
February 05, 2021 02:00 ET
|
Achilles Therapeutics
Achilles Therapeutics Announces Independent Data and Safety Monitoring Committee Review with a Positive Recommendation to Continue with Current Study Design of the Phase I/IIa CHIRON and THETIS Trials...
Achilles Therapeutics Announces Additional Financing Plans
February 05, 2021 01:00 ET
|
Achilles Therapeutics
Achilles Therapeutics Announces Additional Financing Plans London, UK 5 February 2021 – Achilles Therapeutics (“Achilles” or the “Company”), today announced that it expects to consider additional...
Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager
January 08, 2021 07:00 ET
|
Achilles Therapeutics
Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager London, UK 7 January 2021 – Achilles Therapeutics (“Achilles” or the “Company”), a clinical-stage biopharmaceutical...
Achilles Therapeutics Appoints Lee M. Stern as VP, IR & External Communications
December 07, 2020 02:00 ET
|
Achilles Therapeutics
Achilles Therapeutics Appoints Lee M. Stern as VP, IR & External Communications Stevenage, UK 7 December 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company...
Achilles Therapeutics Appoints Robert Coutts as Chief Financial Officer
December 01, 2020 07:00 ET
|
Achilles Therapeutics
Achilles Therapeutics Appoints Robert Coutts as Chief Financial Officer Stevenage, UK 1 December 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing...
Achilles Therapeutics Appoints Robert Coutts as Chief Financial Officer
December 01, 2020 02:00 ET
|
Achilles Therapeutics
Achilles Therapeutics Appoints Robert Coutts as Chief Financial Officer Stevenage, UK 1 December 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing...
Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours
November 19, 2020 07:00 ET
|
Achilles Therapeutics
Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours - Financing includes...
Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours
November 19, 2020 02:00 ET
|
Achilles Therapeutics
Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours - Financing includes...